Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug;52(4):655-668.
doi: 10.1111/apt.15889. Epub 2020 Jul 3.

Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden

Hamed Khalili  1   2 , Åsa H Everhov  2 , Jonas Halfvarson  3 , Jonas F Ludvigsson  2   3 , Johan Askling  2 , Pär Myrelid  4 , Jonas Söderling  2 , Ola Olen  2 , Martin Neovius  2 ; SWIBREG Group
Collaborators, Affiliations

Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden

Hamed Khalili et al. Aliment Pharmacol Ther. 2020 Aug.

Abstract

Background: There are limited data on population-wide assessment of cost in Crohn's disease (CD) and ulcerative colitis (UC).

Aim: To estimate the societal cost of actively treated CD and UC in Sweden.

Methods: We identified 10 117 prevalent CD and 19 762 prevalent UC patients, aged ≥18 years on 1 January 2014 and 4028 adult incident CD cases and 8659 adult incident UC cases (2010-2013) from Swedish Patient Register. Each case was matched to five population comparators. Healthcare costs were calculated from medications, outpatient visits, hospitalisations and surgery. Cost of productivity losses was derived from disability pension and sick leave.

Results: The mean annual societal costs per working-age patient (18-64 years) with CD and UC were $22 813 (vs $7533 per comparator) and $14 136 (vs $7351 per comparator), respectively. In patients aged ≥65 years, the mean annual costs of CD and UC were $9726 and $8072 vs $3875 and $4016 per comparator, respectively. The majority of cost for both CD (56%) and UC (59%) patients originated from productivity losses. Higher societal cost of working-age CD patients as compared to UC patients was related to greater utilisation of anti-TNF (22.2% vs 7.4%) and increased annual disability pension (44 days vs 25 days). Among incident CD and UC patients, the mean total cost over the first year per patient was over three times higher than comparators.

Conclusion: In Sweden, the societal cost of incident and prevalent CD and UC patients was consistently two to three times higher than the general population.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Flow chart of eligible patients
Figure 2:
Figure 2:
Annual mean cost of prevalent patients with CD and UC compared to general population comparators in working age and older adults
Fgure 3:
Fgure 3:
Monthly mean cost in relation to time of diagnosis in incident patients and in general population comparator
Figure 4:
Figure 4:
Cost distribution in prevalent and incident patients and their comparators
See this image and copyright information in PMC

Comment in

References

    1. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018;390:2769–2778. - PubMed
    1. Yarlas A, Rubin DT, Panes J, et al. Burden of Ulcerative Colitis on Functioning and Well-being: A Systematic Literature Review of the SF-36(R) Health Survey. J Crohns Colitis 2018;12:600–609. - PubMed
    1. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907–13. - PMC - PubMed
    1. Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. The American journal of gastroenterology 2003;98:1064–72. - PubMed
    1. Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392–400 e3. - PubMed

Publication types

MeSH terms

Substances